Document:

EX-10.2

 EXHIBIT 10.2 

HEALTHSTREAM, INC. 

RESTRICTED SHARE UNIT AGREEMENT 

This RESTRICTED SHARE UNIT AGREEMENT (this “Agreement”) is made and entered into as of the [•] day of [•] (the “Grant
Date”), between HealthStream, Inc., a Tennessee corporation (together with its Subsidiaries and Affiliates, the “Company”), and [•] (the “Grantee”). Capitalized terms not otherwise defined herein shall have the meaning
ascribed to such terms in the HealthStream, Inc. 2016 Omnibus Incentive Plan (the “Plan”). 
 WHEREAS, the Company has adopted the
Plan, which permits the issuance of Restricted Share Units; and 
 WHEREAS, the Compensation Committee of the Board of Directors of the
Company, including any subcommittee formed pursuant to Section 3.3 of the Plan (the “Committee”) has determined that it would be to the advantage and best interest of the Company and its shareholders to grant an award of the
Restricted Share Units provided for herein to the Grantee as an incentive for increased efforts during his or her term of service or employment with the Company or its Subsidiaries or Affiliates, and has advised the Company thereof and instructed
the undersigned officers to award said Restricted Share Units; 
 NOW, THEREFORE, the parties hereto agree as follows: 

RESTRICTED SHARE UNIT GRANT 
  

					
	 Grantee:
	  	 	[	•] 
	 Aggregate number of Restricted Share Units
	  	 	[	•] 
	 Granted hereunder:
	  			
	 Grant Date:
	  	 	[	•] 

 1. Grant of Restricted Share Unit Award.  

1.1 The Company hereby grants to the Grantee the award (“Award”) of Restricted Share Units (“RSUs”) set forth above on the
terms and conditions set forth in this Agreement and as otherwise provided in the Plan. Each RSU shall have a value equal to the Fair Market Value of one Share. A bookkeeping account will be maintained by the Company to keep track of the RSUs. 

1.2 The Grantee’s rights with respect to the Award shall remain forfeitable at all times prior to the dates on which the RSUs shall vest
in accordance with Section 2 hereof. 

 
This Award may not be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by Grantee other than by will or the laws of descent and distribution. 

2. Vesting and Payment. 

2.1 Vesting. Except as provided in Section 2.2, the RSUs subject to this Award shall vest as follows: 

(i) 1/3 of the RSUs shall vest on the first anniversary of the Grant Date; 

(ii) An additional 1/3 of the RSUs shall vest on the second anniversary of the Grant Date; and 

(iii) The remaining 1/3 of the RSUs shall vest on the third anniversary of the Grant Date. 

2.2 Change in Control. Notwithstanding the foregoing, upon the occurrence of a Change in Control, this Award shall become vested
immediately prior to a Change in Control as to 100% of the RSUs (but only to the extent such Award has not otherwise terminated or become vested). 

2.3 Settlement. The Grantee shall be entitled to settlement of the RSUs subject to this Award at the time that such RSUs vest pursuant
to Section 2.1 or Section 2.2, as applicable. Such settlement shall be made as promptly as practicable thereafter (but in no event after the fifteenth day following the applicable vesting date, or in the case of a Change in
Control, the Change in Control) through the issuance of Shares equal to the number of such vested RSUs. Any settlement of RSUs granted pursuant to this Award shall be made in Shares as evidenced by a “book entry” (i.e., a computerized or
manual entry) in the records of the Company or its designated agent in the name of the Grantee who has become vested in such Shares (or, if requested by Grantee, a stock certificate evidencing such Shares). Notwithstanding the foregoing, if this
Award vests in connection with a Change in Control and the Shares issuable in connection with such vesting subsequently have been converted into or have other been transferred in exchange for other consideration in connection with such Change in
Control, Grantee will be entitled to receive such other consideration in lieu of the converted or transferred Shares. The Grantee will not be entitled to any dividend equivalent or voting rights with regard to the RSUs. 

2.4 Termination. Except as otherwise provided by the Committee, this Award shall not become vested as to any RSUs that have not vested
as of the time of the Grantee’s termination of service with the Company for any reason, and Grantee shall forfeit any unvested RSUs as of the date of such termination of service. 

3. No Right to Continued Service. Nothing in this Agreement or the Plan shall be interpreted or construed to confer upon the Grantee
any right to continue service as a member of the Board. 

 4. Adjustments. The provisions of Section 4.2 and Section 14.3 of
the Plan are hereby incorporated by reference, and the RSUs are subject to such provisions. Any determination made by the Committee pursuant to such provisions shall be made in accordance with the provisions of the Plan and shall be final and
binding for all purposes of the Plan and this Agreement. 
 5. Administration Subject to the Plan. The Grantee hereby acknowledges
receipt of a copy of (or an electric link to) the Plan and agrees to be bound by all the terms and provisions thereof. The terms of this Agreement are governed by the terms of the Plan, and in the case of any inconsistency between the terms of this
Agreement and the terms of the Plan, the terms of the Plan shall govern. The Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are
consistent therewith and to interpret or revoke any such rules. All actions taken and all interpretations and determinations made by the Committee shall be final and binding upon the Grantee, the Company and all other interested persons. No member
of the Committee shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Award. 

6. Modification of Agreement. Subject to the restrictions contained in the Plan and applicable law (including compliance with
Section 409A of the Code), the Committee may waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate, the RSU, prospectively or retroactively. 

7. Section 409A. The Grantee shall be responsible for all taxes due in connection with the grant or vesting or any payment or
transfer with respect to the RSUs and Shares (and cash, if applicable) payable hereunder. Notwithstanding anything herein to the contrary, to the maximum extent permitted by applicable law, the settlement of the RSUs to be made to the Grantee
pursuant to this Agreement is intended to qualify as a “short-term deferral” pursuant to Section 1.409A-1(b)(4) of the Regulations and this Agreement shall be interpreted consistently therewith. However, in any circumstances where the
settlement of the RSUs may not so qualify, the Committee shall administer the grant and settlement of such RSUs in strict compliance with Section 409A of the Code. Further, notwithstanding anything herein to the contrary, to the extent that
this Award constitutes deferred compensation for purposes of Section 409A of the Code (i) no RSU payable upon the Grantee’s termination of service shall be issued, unless Grantee’s termination of service constitutes a
“separation from service” within the meaning of Section 1.409A-1(h) of the Treasury Regulations and (ii) if at the time of a Grantee’s termination of employment with the Company and all “service recipients” (as
defined in the applicable provision of the Treasury Regulations), the Grantee is a “specified employee” as defined in Section 409A of the Code, and the deferral of the commencement of any payments or benefits otherwise payable
hereunder as a result of such termination of service is necessary in order to prevent the imposition of any accelerated or additional tax under Section 409A of the Code, then the Company will defer the commencement of the payment of any such
payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to the Grantee) to the minimum extent necessary to satisfy Section 409A of the Code until the date that is six months and one day
following the Participant’s termination of employment with the Company (or the earliest date as is permitted under Section 409A of the Code), if such payment or benefit is payable upon a termination of employment. Each payment of RSUs
constitutes a “separate payment” for purposes of Section 409A of the Code. Notwithstanding any other provision of this Agreement or the Plan to the contrary, to the extent that this RSU Agreement constitutes deferred compensation for
purposes of Section 409A of the Code, a “Change in Control” for 

 
purposes of this Agreement shall mean “change in the ownership of the Company,” a “change in the effective control of the Company,” or a “change in the ownership of a
substantial portion of the Company’s assets,” as such terms are defined in Section 1.409A-3(i)(5) of the Treasury Regulations. Notwithstanding the foregoing, Company does not warrant that this RSU will qualify for favorable tax
treatment under Section 409A of the Code or any other provision of federal, state, local or foreign law. The Company shall not be liable to Grantee for any tax, interest, or penalties that the Grantee might owe as a result of the grant,
holding, vesting, exercise, or payment of the RSUs. 
 8. No Right to Continued Service. The grant of the RSU shall not be construed
as giving the Grantee the right to be retained in the service of the Company, and the Company may at any time dismiss the Grantee from service, free from any liability or any claim under the Plan. 

9. Severability. If any provision of this Agreement is, or becomes, or is deemed to be invalid, illegal, or unenforceable in any
jurisdiction or as to any Person or the Award, or would disqualify the Plan or Award under any laws deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be
construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be stricken as to such jurisdiction, Person or Award, and the remainder of the Plan and Award
shall remain in full force and effect. 
 10. Governing Law. The validity, interpretation, construction and performance of this
Agreement shall be governed by the laws of the State of Tennessee without giving effect to the conflicts of law principles thereof, except to the extent that such laws are preempted by Federal law. 

11. Successors in Interest. This Agreement shall inure to the benefit of and be binding upon any successor to the Company. This
Agreement shall inure to the benefit of the Grantee’s legal representatives. All obligations imposed upon the Grantee and all rights granted to the Company under this Agreement shall be binding upon the Grantee’s heirs, executors,
administrators and successors. 
 12. Resolution of Disputes. Any dispute or disagreement which may arise under, or as a result of,
or in any way related to, the interpretation, construction or application of this Agreement shall be determined by the Committee. Any determination made hereunder shall be final, binding and conclusive on the Grantee and the Company for all
purposes. 
 13. Notices. All notices required to be given under this Award shall be deemed to be received if delivered or mailed as
provided for herein to the parties at the following addresses, or to such other address as either party may provide in writing from time to time. 
  

			
	 To the Company:
	  	 HealthStream, Inc.
 Cummins Station, Suite
450
 209 10th Avenue South
 Nashville TN 37203

		
	 To the Grantee:
	  	The address then maintained with respect to the Grantee in the Company’s records.

 IN WITNESS WHEREOF, the parties have caused this Restricted Share Unit Agreement to be duly
executed effective as of the day and year first above written. 
  

	
	HEALTHSTREAM, INC.:
	
	  

	 Robert A. Frist, Jr.

Chairman and Chief Executive Officer

	
	 GRANTEE:Exhibit 4.2

 

Addendum
no. 2 to research and license agreement dated april 8, 2010, as amended on june 25, 2012 

 

This Addendum No. 2 to that certain
Research and License Agreement dated April 8, 2010, as amended on June 25, 2012 (the "Agreement"; and this "Addendum"
respective) is made and entered into as of this 19th day of March, 2017, by and among Todos Medical Ltd., a company
organized and existing under the laws of the State of Israel having its principal offices at 1 Hamada Street, Rehovot, Israel (the
“Company”), B.G. Negev Technologies and Applications Ltd. and Mor Research Applications Ltd. (collectively
the “Licensors”)

 

WHEREAS, the Parties wish
to amend the Agreement, a copy of which is attached hereto as Exhibit A as more fully detailed in this Addendum;

 

 

NOW THEREFORE, in consideration
of the premises and the mutual promises herein made, and in consideration of the representations, warranties, and covenants herein
contained, and intending to be legally bound hereby, the Parties agree as follows:

 

		1.	The preamble to this Addendum and exhibits attached hereto form an integral
part hereof.

		2.	All capitalized terms herein shall have the meaning ascribed to them in the
Agreement, unless otherwise defined herein.

		3.	Section 4.1.3 of the Agreement shall be replaced with the following:

 

"4.1.3Minimum
Royalties. For as long as this Agreement is in force and effect, the Company shall pay the Licensors an annual minimum
royalty ("Annual Minimum Royalty") as follows:

 

for the year 2015: USD 10,000;

for the year 2016: USD 25,000

for the year 2017 and for
each full calendar year thereafter that this Agreement is in force and effect: USD 50,000 per year (it being noted that for a partial
year a pro-rata payment shall be due as set forth in Section 4.2.3 below).

 

The Minimum Annual Royalty
paid each calendar year as aforesaid shall be reduced by the Running Royalties and Sublicense Consideration paid to Licensors with
respect to such specific calendar year."

 

		4.	The Parties agree that notwithstanding the terms of the Agreement including
Section 4.1.3 (as replaced pursuant to Section 3 above) and Section 4.2.3, payment of the Annual Minimum Royalty for the years
2015, 2016 and 2017 (in a total amount of USD 85,000 plus applicable VAT) shall be paid by Company to Licensors on the earlier
of (i) August 1, 2017; and (ii) within three (3) days following the date on which the Company shall have received an equity investment
net proceeds pursuant a financing round of not less than USD 10,000,000.

 

		5.	All other terms of the Agreement shall remain unchanged.

 

 

IN WITNESS WHEREOF, the
Parties hereto have executed this Addendum on the date first above written.

 

 

	Todos Medical Ltd.		B.G. Technologies and Applications Ltd.	 	Mor Research Applications Ltd.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]